目的 探讨平消胶囊联合TPF方案（多西他赛+顺铂+氟尿嘧啶）治疗局部晚期喉癌的临床疗效。方法 选取2013年3月—2017年3月在内蒙古林业总医院治疗的78例局部晚期喉癌患者为研究对象，根据用药的差别将患者分为对照组（39例）和治疗组（39例）。对照组患者给予TPF方案治疗，在第1天静脉滴注多西他赛注射液75 mg/m²，持续30 min以上；第1～3天静脉滴注顺铂注射液40 mg/m²，第1～5天静脉滴注氟尿嘧啶注射液750 mg/m²；治疗组在对照组组治疗的基础上鼻饲平消胶囊，1.84 g/次，3次/d。两组均以21 d为1个周期，共治疗3个周期。观察两组患者的临床疗效，比较两组治疗前后的WHO生存质量评估简表（WHOQOL-BREF）评分、肿瘤标志物水平和血清学指标水平。结果 治疗后，对照组客观缓解率（ORR）、临床获益率（CBR）分别为46.15%、69.23%，均显著低于治疗组的66.67%、89.74%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组生理维度、心理维度、社会关系领域和环境领域评分均显著升高，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗组WHOQOL-BREF评分显著高于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组血清糖抗原72-4（CA72-4）、糖抗原19-9（CA19-9）、鳞状细胞癌相关抗原（SCC-Ag）和细胞角蛋白19片段（CYFRA21-1）水平均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗组肿瘤标志物水平显著低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组血清可溶性肿瘤坏死因子受体I（sTNFRI）、血管内皮生长因子（VEGF）、基质金属蛋白酶-9（MMP-9）、β₂微球蛋白（β₂-MG）水平均降低，同组治疗前后比较差异具有统计学意义（P<0.05），且治疗组显著低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 平消胶囊联合TPF方案治疗局部晚期喉癌疗效显著，可提高患者生活质量，降低机体肿瘤标志物水平，抑制血管新生因子和细胞侵袭分子水平，提高机体免疫能力，具有较好的临床推广应用价值。

Objective To investigate the clinical efficacy of Pingxiao Capsules combined with TPF regimen (docetaxel + cisplatin + fluorouracil) in treatment of locally advanced laryngeal cancer. Methods Patients (78 cases) with locally advanced laryngeal cancer in Inner Mongolia Forestry General Hospital from March 2013 to March 2017 were divided into control (39 cases) and treatment (39 cases) groups according to the difference of medication. Patients in the control group were given TPF regimen. Patients were iv administered with Docetaxel Injection 75 mg/m² on the first day for more than 30 min, iv administered with Cisplatin Injection 40 mg/m² at the first day to the third day, and iv administered with Fluorouracil Injection 750 mg/m² at the first day to the fifth day. Patients in the treatment group were nasal feeding administered with Pingxiao Capsules on the basis of the control group, 1.84 g/time, three times daily. A treatment cycle had 21 d, and patients in two groups were treated for 3 cycles. After treatment, the clinical efficacy was evaluated, and the WHOQOL-BREF scores, tumor markers levels, and the serological indexes levels in two groups before and after treatment were compared. Results After treatment, the ORR and CBR in the control group were 46.15% and 69.23%, which were significantly lower than 66.67% and 89.74% in the treatment group, respectively, and there were differences between two groups (P < 0.05). After treatment, the scores of physiological dimension, psychological dimension, social relation field, and environment field in two groups were significantly increased, and the difference were statistically significant in the same group (P< 0.05). And the WHOQOL-BREF scores in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P< 0.05). After treatment, the serum levels of CA72-4, CA19-9, SCC-Ag, and CYFRA21-1 in two groups were significantly decreased, and the difference were statistically significant in the same group (P< 0.05). And the tumor markers levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P< 0.05). After treatment, the serum levels of sTNFRI, VEGF, MMP-9, and β₂-MG in two groups were significantly decreased, and the difference were statistically significant in the same group (P< 0.05). And the serological indexes levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P< 0.05). Conclusion Pingxiao Capsules combined with TPF regimen has a significant effect in treatment of locally advanced laryngeal cancer, which can improve the patient's quality of life, reduce the levels of tumor markers, inhibit the levels of angiogenic factors and cell invasion molecules, and improve the immune capacity, which has a certain clinical application value.